Next Article in Journal
The Immunotherapy Landscape in Adrenocortical Cancer
Next Article in Special Issue
A Novel Signature of CCNF-Associated E3 Ligases Collaborate and Counter Each Other in Breast Cancer
Previous Article in Journal
Organoids and Colorectal Cancer
 
 
Review

Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer

by 1,* and 2,3,4
1
Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
2
Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
3
Department of Obstetrics, Gynecology & Reproductive Sciences, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
4
CancerCare Manitoba Research Institute, Winnipeg, MB R3E 0V9, Canada
*
Author to whom correspondence should be addressed.
Academic Editors: George Mosialos and Deborah J. Marsh
Cancers 2021, 13(11), 2659; https://doi.org/10.3390/cancers13112659
Received: 3 April 2021 / Revised: 22 May 2021 / Accepted: 24 May 2021 / Published: 28 May 2021
(This article belongs to the Special Issue Ubiquitin: What It Is and Its Role in Targeted Cancer Therapy)
In this review, public datasets were mined in an attempt to identify genes that code for proteins of the ubiquitin proteasome system that can be used as therapeutic targets in high-grade serous ovarian cancer. In this study, we found that more than 50 genes coding for ubiquitin ligases and more than 100 for ubiquitin ligase adaptors were differentially expressed between the low malignant potential tumors and the malignant invasive ovarian tumors. We conclude that several genes coding for the ubiquitin ligases and their adaptors have a potential to serve as therapeutic targets in high-grade serous ovarian cancer.
In this article, we reviewed the transcription of genes coding for components of the ubiquitin proteasome pathway in publicly available datasets of epithelial ovarian cancer (EOC). KEGG analysis was used to identify the major pathways distinguishing EOC of low malignant potential (LMP) from invasive high-grade serous ovarian carcinomas (HGSOC), and to identify the components of the ubiquitin proteasome system that contributed to these pathways. We identified elevated transcription of several genes encoding ubiquitin conjugases associated with HGSOC. Fifty-eight genes coding for ubiquitin ligases and more than 100 genes encoding ubiquitin ligase adaptors that were differentially expressed between LMP and HGSOC were also identified. Many differentially expressed genes encoding E3 ligase adaptors were Cullin Ring Ligase (CRL) adaptors, and 64 of them belonged to the Cullin 4 DCX/DWD family of CRLs. The data suggest that CRLs play a role in HGSOC and that some of these proteins may be novel therapeutic targets. Differential expression of genes encoding deubiquitinases and proteasome subunits was also noted. View Full-Text
Keywords: ovarian cancer; transcriptome; ubiquitin ligase ovarian cancer; transcriptome; ubiquitin ligase
Show Figures

Figure 1

MDPI and ACS Style

Vriend, J.; Nachtigal, M.W. Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer. Cancers 2021, 13, 2659. https://doi.org/10.3390/cancers13112659

AMA Style

Vriend J, Nachtigal MW. Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer. Cancers. 2021; 13(11):2659. https://doi.org/10.3390/cancers13112659

Chicago/Turabian Style

Vriend, Jerry, and Mark W. Nachtigal. 2021. "Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer" Cancers 13, no. 11: 2659. https://doi.org/10.3390/cancers13112659

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop